Skip to content

Validation of echocardiographic features in foetuses

Validation of echocardiographic features in foetuses - Foetal echocardiographic features

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON55695
Enrollment
140
Registered
2019-08-28
Start date
2019-12-12
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

long QT syndrome LQTS

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: * The mother must be living in The Netherlands. * The mother is between 18 and 40 years of age. * The mother should be pregnant and have had standard obstetric care without abnormalities

Exclusion criteria

Exclusion criteria: * Maternal medical history of conditions that are at risk for affecting the foetus (i.e pregestational diabetes, epilepsy, HIV, hepatitis B) * Maternal use of medication that affects the QTc-interval (https://crediblemeds.org/pdftemp/pdf/CombinedList.pdf) * Foetuses of consanguineous parents * Foetuses with congenital heart disease, chromosomal syndromes, cephalic disorders * Maternal cigarette or alcohol usage during pregnancy * Maternal obesity before pregnancy (BMI * 30) * Abnormalities on the previous foetal ultrasound.

Design outcomes

Primary

MeasureTime frame
The LVIRT and the myocardial contraction duration will be measured using respectively echocardiographic Doppler tracings and cTDI at a foetal age around 20, 28 and 30 weeks* gestation.

Secondary

MeasureTime frame
Other mechanical foetal echocardiographic parameters at 20, 28 en 30 weeks' gestation.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)